The clinical use of doxorubicin in cancer is limited by cardiotoxic effects that can lead to heart failure. Whereas earlier work focused on the direct impact of doxorubicin on cardiomyocytes, recent studies have turned to the endothelium, because doxorubicin-damaged endothelial cells can trigger the development and progression of cardiomyopathy by decreasing the release and activity of key endothelial factors and inducing endothelial cell death. Thus, the endothelium represents a novel target for improving the detection, management, and prevention of doxorubicin-induced cardiomyopathy.
T he anthracycline doxorubicin is an antineoplastic agent widely used in the treatment of breast, lung, ovarian, thyroid, and gastric cancers (1) . Because it is amphoteric, doxorubicin is able to translocate into a variety of subcellular compartments, where it disrupts the integrity of intracellular deoxyribonucleic acid (DNA), proteins, and lipid molecules (2) . These toxic insults are not restricted to cancer cells, and doxorubicin-associated cardiotoxicity is, in fact, a result of the damage it exerts on noncancerous cells, especially cardiomyocytes (2) .
Because doxorubicin is administered into the systemic circulation, the first cellular contact the drug makes is with the endothelium (2) . Accordingly, doxorubicin therapy can first trigger detrimental changes to endothelial cells before it travels into other tissues such as the heart. This review will detail the importance of the endothelium in maintaining the health and function of cardiomyocytes and discuss how doxorubicin-mediated endothelial cell death and dysfunction contribute to the development and progression of cardiomyopathy. Doxorubicin therapy is associated with both acute and chronic cardiotoxicity. Acute cardiotoxicity has an incidence of approximately 11% and typically manifests within days after doxorubicin treatment has been initiated (3) . Acute cardiotoxicity is usually reversible and often presents as myopericarditis, cardiac dysrhythmias, and left ventricular (LV) dysfunction (4, 5) .
Conversely, chronic cardiotoxicity, although significantly less prevalent than acute cardiotoxicity, is currently irreversible (6) , has an appreciably poorer prognosis (7) , and usually presents months or even years after treatment is completed (8) . In the initial stages, chronic cardiotoxicity typically presents as LV dysfunction with progression to cardiomyopathy (9, 10) . Some patients with chronic cardiotoxicity can go on to develop heart failure, a severe condition associated with a 1-year mortality rate of 50% (7) . In view of the severe implications of chronic cardiotoxicity, patients treated with doxorubicin should be longitudinally monitored for features that suggest the reduction of LV function and cardiomyopathy.
WHAT RISK FACTORS CONTRIBUTE TO DOXORUBICIN-MEDIATED CARDIOTOXICITY?
A myriad of factors have been postulated to elevate the risk of doxorubicin-induced cardiomyopathy. Luu et al.
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damage. A variety of diagnostic tools are currently used to detect doxorubicin-mediated cardiomyopathy. The gold standard is endomyocardial biopsy, which will reveal vacuolization of the cytoplasm, loss of myofibrils, and enlargement of the sarcoplasm reticulum in cardiomyocytes if myopathy is present (6, 14) . However, this procedure requires intensive training and is invasive (6) . Echocardiography and radionuclide ventriculography are more commonly used but often fail to detect early doxorubicininduced cardiac damage (14, 29) . This is likely because a significant change in LV systolic function, which these techniques assess, does not occur until the heart has undergone substantial damage (30) .
Clearly, the technologies currently available for early detection of doxorubicin-induced cardiotoxicity have room for improvement.
To date, there is no definitive treatment indicated to prevent or reverse doxorubicin-induced chronic cardiotoxicity (6) . Once chronic cardiomyopathy is The semiquinone anion then passes the electron to molecular oxygen, forming a superoxide radical (41) .
Under normal rates of superoxide production, superoxide dismutase will convert the radical to hydrogen peroxide, which is further detoxified by catalase and glutathione peroxidase (43, 44) . However, when doxorubicin-induced oxidative stress exceeds endothelial cell antioxidant capacity, toxic metabolites will begin to accumulate (43) . The superoxide radical is also produced from the complex of doxorubicin and iron (45) . Notably, the drug-iron complex converts hydrogen peroxide to hydroxyl radicals, which are a more damaging form of ROS (45). 
DISRUPTION OF THE ENDOTHELIAL CELL-CARDIOMYOCYTE SIGNALING AXIS
Perfusion of the heart is mainly driven by the left and Notably, angiotensin-converting enzyme inhibitors 
